Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-01

Study Completion Date

2050-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators aim to learn more about symptoms suggestive of a neurodegenerative process.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

NCT02740634

Atypical Alzheimer's Disease Logopenic Progressive Aphasia (LPA) Posterior Cortical Atrophy (PCA) +5 more

RECRUITING NA

A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's Disease

NCT06057909

Lewy Body Disease Alzheimer Disease Healthy

RECRUITING

PiB PET Scanning in Speech and Language Based Dementias

NCT01623284

PPA Primary Progressive Aphasia Aphasia +5 more

COMPLETED PHASE1

Neuroimaging Study

NCT03618186

Cognitive Impairment

ENROLLING_BY_INVITATION PHASE2

Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia

NCT02736695

Primary Progressive Aphasia Behavioral Variant of Frontotemporal Dementia Frontotemporal Dementia, Behavioral Variant

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will recruit participants with symptoms suggestive of a neurodegenerative and/or related disease. Participants could be evaluated on a yearly basis, undergoing a baseline visit and possible follow-up evaluations with an interval of one year. At each visit, participants could undergo any combination of the following based on their symptoms and complaints: a neurological assessment, a speech/language assessment, a neuropsychometric assessment, an MRI, an FDG PET/CT scan, a PiB PET/CT scan, a Tau PET/CT scan and/or a C-11 ER176 PET/CT scan. All participants will be asked to provide a blood sample to allow for future genetic studies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PSP CBD PCA LPA Semantic Dementia Semantic Aphasia Behavioral Variant of Frontotemporal Dementia FTD PPA Apraxia of Speech MSA - Multiple System Atrophy Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neurodegenerative symptoms

C-11 PiB

Intervention Type DRUG

Completing PET scan looking for amyloid protein

AV1451 Tau

Intervention Type DRUG

Completing PET scan looking for tau protein

C-11 ER176

Intervention Type DRUG

Completing PET scan looking for neuroinflammation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

C-11 PiB

Completing PET scan looking for amyloid protein

Intervention Type DRUG

AV1451 Tau

Completing PET scan looking for tau protein

Intervention Type DRUG

C-11 ER176

Completing PET scan looking for neuroinflammation

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All participants will be over the age of 21
* Have symptoms suggestive of a neurodegenerative and/or related disorder

Exclusion Criteria

* Participants will be excluded if they have any concurrent illnesses that could account for all of their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes
* Women that are pregnant or post-partum and breast-feeding will be excluded
* Participants will be excluded if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, Hypogammaglobulinemia, Wiskott-Aldrich syndrome and Down's syndrome
* Participants will be excluded if MRI is contraindicated (metal in head, cardiac pace maker, etc), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts)
* Participants will be excluded if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy)

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No